Tyrosine kinase inhibitors (TKIs) are transformative agents for the treatment of NSCLC, especially in terms of epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK). This evidence concerns the gene EGFR and non-small cell lung carcinoma.